BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38047111)

  • 1. Association of HMGCR inhibition with rheumatoid arthritis: a Mendelian randomization and colocalization study.
    Ma L; Du Y; Ma C; Liu M
    Front Endocrinol (Lausanne); 2023; 14():1272167. PubMed ID: 38047111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study.
    Qiao L; Lv S; Meng K; Yang J
    Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
    Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM
    JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
    Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
    PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
    Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
    Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes.
    Liu G; Shi M; Mosley JD; Weng C; Zhang Y; Lee MTM; Jarvik GP; Hakonarson H; Namjou-Khales B; Sleiman P; Luo Y; Mentch F; Denny JC; Linton MF; Wei WQ; Stein CM; Feng Q
    JAMA Netw Open; 2021 Jun; 4(6):e2112820. PubMed ID: 34097045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential association of genetically predicted lipid and lipid-modifying drugs with rheumatoid arthritis: A Mendelian randomization study.
    Huang Z; Cui T; Yao J; Wu Y; Zhu J; Yang X; Cui L; Zhou H
    PLoS One; 2024; 19(2):e0298629. PubMed ID: 38416767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between genetically proxied HMGCR inhibition and male reproductive health: A Mendelian randomization study.
    Yan Z; Xu Y; Li K; Liu L
    Medicine (Baltimore); 2023 Sep; 102(39):e34690. PubMed ID: 37773823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
    Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
    PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
    Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
    Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating genetically mimicked effects of statins via HMGCR inhibition on immune-related diseases in men and women using Mendelian randomization.
    Yang G; Schooling CM
    Sci Rep; 2021 Dec; 11(1):23416. PubMed ID: 34862478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study.
    Ference BA; Majeed F; Penumetcha R; Flack JM; Brook RD
    J Am Coll Cardiol; 2015 Apr; 65(15):1552-61. PubMed ID: 25770315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study.
    Huang W; Xiao J; Ji J; Chen L
    Elife; 2021 Dec; 10():. PubMed ID: 34866576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study.
    Soremekun O; Karhunen V; He Y; Rajasundaram S; Liu B; Gkatzionis A; Soremekun C; Udosen B; Musa H; Silva S; Kintu C; Mayanja R; Nakabuye M; Machipisa T; Mason A; Vujkovic M; Zuber V; Soliman M; Mugisha J; Nash O; Kaleebu P; Nyirenda M; Chikowore T; Nitsch D; Burgess S; Gill D; Fatumo S
    EBioMedicine; 2022 Apr; 78():103953. PubMed ID: 35325778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMG-CoA reductase is a potential therapeutic target for migraine: a mendelian randomization study.
    Qu K; Li MX; Yu P; ; Wu BH; Shi M; Dong M
    Sci Rep; 2024 May; 14(1):12094. PubMed ID: 38802400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between lipid-lowering drugs and pregnancy and perinatal outcomes: a Mendelian randomization study.
    Wang R; Zhao J; Li L; Huo Y
    J Hypertens; 2024 Apr; 42(4):727-734. PubMed ID: 38230624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic insights into the association of statin and newer nonstatin drug target genes with human longevity: a Mendelian randomization analysis.
    Chen H; Zhou X; Hu J; Li S; Wang Z; Zhu T; Cheng H; Zhang G
    Lipids Health Dis; 2023 Dec; 22(1):220. PubMed ID: 38082436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
    He JY; Zhang X; Wang K; Lv WQ
    J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mendelian Randomization Study of
    Ference BA; Ray KK; Catapano AL; Ference TB; Burgess S; Neff DR; Oliver-Williams C; Wood AM; Butterworth AS; Di Angelantonio E; Danesh J; Kastelein JJP; Nicholls SJ
    N Engl J Med; 2019 Mar; 380(11):1033-1042. PubMed ID: 30865797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Causal relationship between lipid-lowering drugs and ovarian cancer, cervical cancer: a drug target mendelian randomization study.
    Li J; Yang Z; Wang T; Li M; Wu X; Fu X; Yang C; Li Y; Wang X; Lan Z; Li M; Chen S
    BMC Cancer; 2024 May; 24(1):667. PubMed ID: 38822303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.